Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Tempus AI, Inc. Class A Common Stock (TEM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: TEM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $71
1 Year Target Price $71
| 4 | Strong Buy |
| 2 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.2% | Avg. Invested days 17 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.80B USD | Price to earnings Ratio 34.26 | 1Y Target Price 71 |
Price to earnings Ratio 34.26 | 1Y Target Price 71 | ||
Volume (30-day avg) 12 | Beta - | 52 Weeks Range 31.36 - 91.45 | Updated Date 08/29/2025 |
52 Weeks Range 31.36 - 91.45 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.15 |
Earnings Date
Report Date 2025-08-08 | When - | Estimate -0.25 | Actual -0.22 |
Profitability
Profit Margin -20.98% | Operating Margin (TTM) -19% |
Management Effectiveness
Return on Assets (TTM) -11.51% | Return on Equity (TTM) -97.95% |
Valuation
Trailing PE 34.26 | Forward PE - | Enterprise Value 13358717921 | Price to Sales(TTM) 13.44 |
Enterprise Value 13358717921 | Price to Sales(TTM) 13.44 | ||
Enterprise Value to Revenue 14.03 | Enterprise Value to EBITDA - | Shares Outstanding 168684000 | Shares Floating 101696638 |
Shares Outstanding 168684000 | Shares Floating 101696638 | ||
Percent Insiders 41.83 | Percent Institutions 44.06 |
Upturn AI SWOT
Tempus AI, Inc. Class A Common Stock
Company Overview
History and Background
Tempus AI, Inc. was founded in 2015. It is a technology company focused on precision medicine through the use of AI and data analytics, particularly in oncology. It has rapidly evolved into a key player in the healthcare data space.
Core Business Areas
- Data and Insights: Tempus gathers and analyzes multi-modal data (genomic, imaging, clinical) to generate insights for healthcare providers and researchers.
- Therapeutics: Tempus develops and commercializes precision medicine solutions and therapeutic programs based on its data and AI capabilities.
- Clinical Trials: Tempus facilitates clinical trials by connecting patients with appropriate studies based on their genomic and clinical profiles.
Leadership and Structure
Eric Lefkofsky is the founder and CEO. The company has a typical corporate structure with departments focused on technology, research, operations, and commercial activities. The company went IPO on June 14, 2024. Listed on the NASDAQ as TEM.
Top Products and Market Share
Key Offerings
- Tempus xT: A comprehensive genomic sequencing test for cancer, providing insights into a patient's tumor profile. Market share data is not publicly available; Tempus is a key competitor with Foundation Medicine, Guardant Health, and Caris Life Sciences.
- Tempus ONE: An AI-enabled platform aggregating clinical, genomic, and imaging data to accelerate drug discovery and development. Market share data is not publicly available; competitors include Flatiron Health (acquired by Roche) and ConcertAI.
- Tempus nT: Liquid biopsy test. Market share data is not publicly available; competitors include Guardant Health.
Market Dynamics
Industry Overview
The precision medicine industry is growing rapidly, driven by advancements in genomics, data analytics, and AI. There is increasing demand for personalized treatment approaches, particularly in oncology.
Positioning
Tempus is positioned as a leader in AI-driven precision medicine, with a large and growing database of genomic and clinical information. Its competitive advantage lies in its integrated platform and data analytics capabilities.
Total Addressable Market (TAM)
The global precision medicine market is projected to reach hundreds of billions of dollars. Tempus aims to capture a significant share of this market by providing comprehensive data solutions and personalized treatment options.
Upturn SWOT Analysis
Strengths
- Large and growing multi-modal data repository
- Advanced AI and machine learning capabilities
- Integrated platform for data analysis and therapeutic development
- Strong relationships with leading cancer centers and research institutions
- Founder led by Eric Lefkofsky who has had other successful tech companies.
Weaknesses
- High operating expenses
- Requires signficant capital investment
- Data security and privacy concerns
- Dependence on partnerships with healthcare providers
- Still losing money. Not profitable.
Opportunities
- Expansion into new therapeutic areas beyond oncology
- Development of novel diagnostics and therapeutics
- Strategic partnerships with pharmaceutical companies
- Increased adoption of precision medicine in clinical practice
- Potential for international expansion
Threats
- Competition from established diagnostic companies
- Regulatory hurdles and reimbursement challenges
- Data privacy and security breaches
- Ethical concerns surrounding AI in healthcare
- Erosion of the IPO lockup once it has cleared.
Competitors and Market Share
Key Competitors
- Foundation Medicine (RHHBY)
- Guardant Health (GH)
- Caris Life Sciences
Competitive Landscape
Tempus competes with other diagnostic and data analytics companies. Its strengths include its integrated platform, large data repository, and AI capabilities. Competitors may have advantages in specific areas, such as established relationships with oncologists or specialized diagnostic tests.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends demonstrate strong revenue increase. However, lack of profitability continues to be a hurdle.
Future Projections: Analyst projections suggest continued revenue growth, driven by expanding product offerings and market penetration. Profitability is expected to improve over time, but the timeline remains uncertain.
Recent Initiatives: Recent strategic initiatives include expansion of the Tempus ONE platform, partnerships with pharmaceutical companies for drug development, and investment in AI research.
Summary
Tempus AI is a rapidly growing company in the precision medicine space, leveraging AI and data analytics to improve cancer care. While it has a strong platform and significant growth potential, it is not yet profitable and faces competition from established players. The company's success hinges on its ability to execute its growth strategy and achieve profitability in a rapidly evolving market. The company must also focus on data security and address regulatory challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Tempus AI, Inc. SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is based on estimates and may not be precise. Financial data is subject to change and should be verified with official sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tempus AI, Inc. Class A Common Stock
Exchange NASDAQ | Headquaters Chicago, IL, United States | ||
IPO Launch date 2024-06-14 | Co-Founder, CEO, President & Chairman Mr. Eric P. Lefkofsky J.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 2400 | Website https://www.tempus.com |
Full time employees 2400 | Website https://www.tempus.com | ||
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology, as well as strategic collaboration with Personalis, Inc. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.